The stock is in a strong uptrend, with a 1-year price change of +88.3%, significantly outperforming the S&P 500's +19.1%. Currently trading at $555.91, it sits at 82.4% of its 52-week range ($272.12 low to $609.35 high), indicating it is near the upper end but not overextended. This positioning suggests sustained bullish momentum, though the stock has pulled back from its 52-week high of $609.35, offering a potential entry point for momentum investors. Short-term momentum shows a mixed picture: the 1-month change is +2.9%, while the 3-month change is -1.6%, indicating a deceleration from the longer-term uptrend. This divergence could signal a consolidation phase or a temporary pullback within the broader uptrend, as the stock has corrected from its March highs. The relative strength index (RSI) is not provided, but the price action suggests a pause rather than a reversal. Key support is at the 52-week low of $272.12, a level not tested in over a year, while resistance is at the 52-week high of $609.35. A breakout above $609.35 would signal a resumption of the uptrend, while a breakdown below recent support near $540 could indicate further weakness. With a beta of 0.58, the stock is significantly less volatile than the market, making it a lower-risk holding within a portfolio.

Revenue has grown steadily, with the most recent quarter (Q4 2025) reporting $790.2 million, up 7.4% year-over-year from $735.9 million in Q4 2024. The trailing twelve-month revenue is approximately $3.18 billion, with consistent sequential growth from $677.7 million in Q1 2024 to $799.5 million in Q3 2025. Tyvaso remains the primary growth driver, contributing $464.3 million in the latest quarter, while Remodulin ($128 million) and Orenitram ($121.2 million) provide stable contributions. The growth trajectory is solid but decelerating from the double-digit rates seen in early 2024, suggesting a maturing product portfolio. Profitability is robust, with net income of $364.3 million in Q4 2025 and a net margin of 46.1%, up from 40.9% in Q4 2024. Gross margin remains high at 86.9%, reflecting the company's pricing power and efficient manufacturing. Operating margin improved to 45.1% from 48.6% a year ago, indicating slight cost pressure but still industry-leading. The company is highly profitable with a trailing P/E of 16.2x and a forward P/E of 17.5x, reflecting strong earnings generation. The balance sheet is fortress-like: debt-to-equity is 0, and the current ratio is 6.6x, indicating ample liquidity. Free cash flow (TTM) is $1.04 billion, providing significant financial flexibility for R&D, acquisitions, or share buybacks. ROE is 18.8%, demonstrating efficient capital allocation.